CMCIX | VEXRX | CMCIX / VEXRX | |
Total Expense Ratio | 0.89 | 0.34 | 262% |
Annual Report Gross Expense Ratio | 1.02 | 0.34 | 300% |
Fund Existence | 14 years | 23 years | - |
Gain YTD | -9.825 | -13.374 | 73% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 50000 | 2,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 30.8M | 19.8B | 0% |
Annual Yield % from dividends | 0.41 | 0.56 | 72% |
Returns for 1 year | -7.74 | -11.24 | 69% |
Returns for 3 years | -7.84 | -8.96 | 88% |
Returns for 5 years | 21.90 | 17.63 | 124% |
Returns for 10 years | 0.54 | 0.85 | 63% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
XBI | 80.89 | 1.79 | +2.26% |
SPDR® S&P Biotech ETF | |||
FEP | 42.41 | 0.74 | +1.78% |
First Trust Europe AlphaDEX® ETF | |||
SBIO | 28.51 | 0.49 | +1.75% |
ALPS Medical Breakthroughs ETF | |||
BCDF | 28.98 | 0.44 | +1.54% |
Horizon Kinetics Blockchain Dev ETF | |||
CHI | 9.92 | 0.14 | +1.43% |
Calamos Convertible Opportunities and Income Fund |